0001104659-22-108137.txt : 20221012 0001104659-22-108137.hdr.sgml : 20221012 20221012165945 ACCESSION NUMBER: 0001104659-22-108137 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20221007 ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Other Events FILED AS OF DATE: 20221012 DATE AS OF CHANGE: 20221012 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Future Health ESG Corp. CENTRAL INDEX KEY: 0001851182 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] IRS NUMBER: 862305680 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40788 FILM NUMBER: 221307319 BUSINESS ADDRESS: STREET 1: 8 THE GREEN STREET 2: SUITE # 12081 CITY: DOVER STATE: DE ZIP: 19901 BUSINESS PHONE: 833-388-8734 MAIL ADDRESS: STREET 1: 8 THE GREEN STREET 2: SUITE # 12081 CITY: DOVER STATE: DE ZIP: 19901 8-K 1 tm2228104d1_8k.htm FORM 8-K
0001851182 false 0001851182 2022-10-07 2022-10-07 0001851182 fhlt:UnitsEachConsistingOfOneShareOfCommonStockAndOnehalfOfOneRedeemableWarrantMember 2022-10-07 2022-10-07 0001851182 us-gaap:CommonStockMember 2022-10-07 2022-10-07 0001851182 fhlt:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember 2022-10-07 2022-10-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 12, 2022 (October 7, 2022)

 

Future Health ESG Corp.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40788   86-2305680
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

8 The Green, Suite 12081

Dover, DE 46260

(Address of principal executive offices, including zip code)

 

(833) 388-8734

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  x Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading Symbol(s)

  

Name of each exchange on which registered

Units, each consisting of one share of common stock and one-half of one redeemable warrant   FHLTU   The Nasdaq Stock Market LLC
Common stock, par value $0.0001 per share   FHLT   The Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share   FHLTW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 1.02. Termination of a Material Definitive Agreement.

 

The information set forth below in Item 8.01 of this Report is incorporated by reference herein.

 

Item 8.01. Other Events.

 

On October 7, 2022, Future Health ESG Corp. (“Future Health”) and Variant Capital Limited (“Variant”), by mutual written agreement, terminated the previously disclosed Subscription Agreement, effective as of June 13, 2022 (the “Subscription Agreement”), pursuant to which, among other things, Variant agreed to purchase an aggregate of 9,090,909 shares of common stock of Future Health at a cash purchase price of $11.00 per share immediately prior to the closing of the previously announced business combination (the “Business Combination”) between Future Health and Excelera DCE, a California corporation (“Excelera”). Pursuant to the mutual written termination agreement, the Subscription Agreement is of no further force and effect, and all rights and obligations of the parties thereunder have terminated.

 

Also on October 7, 2022, Future Health and Hakim Holding Group Company Limited (“Hakim”), by mutual written agreement, terminated the previously disclosed Forward Purchase Agreement, effective as of June 13, 2022 (the “Forward Purchase Agreement”), pursuant to which, among other things, Hakim agreed to purchase shares of common stock of Future Health in open market purchases at an aggregate purchase price of $20,000,000 prior to the date which is two (2) business days prior to the date of the special meeting of Future Health’s stockholders called in connection with the Business Combination and purchase from Future Health, immediately prior to the Business Combination, the requisite number of shares at $11.00 per share to satisfy any unfulfilled portion of the $20,000,000 purchase commitment. Pursuant to the mutual written termination agreement, the Forward Purchase Agreement is of no further force and effect, and all rights and obligations of the parties thereunder have terminated.

 

Future Health is in discussions to secure alternative strategic financing, which management expects will be less dilutive to Future Health stockholders. Termination of the Subscription Agreement and the Forward Purchase Agreement is not expected to impact Excelera’s operations or delay closing of the Business Combination.

 

Important Information for Stockholders

 

This Current Report on Form 8-K does not constitute an offer to sell or the solicitation of an offer to buy any securities or constitute a solicitation of any vote or approval. This Current Report on Form 8-K shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom.

 

In connection with the Business Combination, Future Health has filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (File No. 333-266319) (as may be amended from time to time, the “Registration Statement”), which includes a preliminary proxy statement for Future Health. Future Health also plans to file other documents with the SEC regarding the Business Combination. After the Registration Statement has been declared effective by the SEC, a definitive proxy statement will be mailed to the stockholders of Future Health. STOCKHOLDERS OF FUTURE HEALTH ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND OTHER DOCUMENTS RELATING TO THE PROPOSED TRANSACTIONS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTIONS. Stockholders will be able to obtain free copies of the proxy statement and other documents containing important information about Future Health and Excelera once such documents are filed with the SEC, through the website maintained by the SEC at http://www.sec.gov or by directing a request to: 8 The Green Suite 12081, Dover, DE 19901.

 

 

 

 

Participants in the Solicitation

 

Future Health and Excelera and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Future Health in connection with the Business Combination. Securityholders of Future Health and other interested persons may obtain more information regarding the names and interests in the proposed Business Combination of Future Health’s directors and officers in Future Health’s filings with the SEC, including the Registration Statement, which also contains the names and interests in the proposed Business Combination of Excelera’s directors and officers. These documents can be obtained free of charge from the sources indicated above.

 

 Forward Looking Statements

 

The information included herein and in any oral statements made in connection herewith include forward-looking statements within the meaning of the federal securities laws, which statements involve substantial risks and uncertainties. These statements are based on the beliefs and assumptions of the respective management teams of Future Health, Excelera and MacArthur Court Acquisition Corp. (“Seller”). Although Future Health, Excelera and Seller believe that their respective plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, none of Future Health, Excelera or Seller can assure you that it will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Forward-looking statements generally relate to future events or future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” or “continue” or the negative of these words or other similar terms or expressions that concern Future Health, Excelera or Seller’s expectations, strategy, plans or intentions. Forward-looking statements contained in this Current Report on Form 8-K include statements about:

 

  ● the anticipated benefits of the Business Combination;

 

  ● the ability of Future Health, Excelera and the Seller to complete the Business Combination, including obtainment of alternative strategic financing and satisfaction or waiver of the conditions to the Business Combination;

 

  ● the anticipated costs associated with the proposed Business Combination;

 

  ● Excelera’s financial and business performance following the Business Combination, including financial projections and business metrics;

 

  ● Excelera’s ability to effectively grow and to effectively expand operations;

 

  ● the potential business or economic disruptions caused by current and future pandemics, such as the COVID-19 pandemic;

 

  ● the ability to obtain and/or maintain the listing of Future Health’s common stock and the warrants on Nasdaq, and the potential liquidity and trading of its securities;

 

  ● the risk that the proposed Business Combination disrupts current plans and operations of Excelera as a result of the announcement and consummation of the proposed Business Combination;

 

  ● the ability to recognize the anticipated benefits of the proposed Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, and retain its key employees;

 

  ● changes in applicable laws or regulations;

 

 

 

 

  ● Excelera’s ability to raise financing in the future;

 

  ● Excelera’s officers and directors allocating their time to other businesses and potentially having conflicts of interest with Excelera’s business or in approving the Business Combination;

 

  ● the projected financial information, growth rate, strategies, and market opportunities for Excelera;

 

  ● Excelera’s ability to successfully expand in its existing markets and into new markets;

 

  ● Exelera’s ability to provide physicians with precision medicine insights and financial resources;

 

  ● Excelera’s ability, assessment of and strategies to compete with its competitors;

 

  ● the success of Excelera’s marketing strategies;

 

  ● Excelera’s ability to attract and retain talent and the effectiveness of its compensation strategies and leadership;

 

  ● general economic conditions and their impact on demand for the Excelera platform;

 

  ● Excelera’s ability to maintain its licenses and operate in regulated industries;

 

  ● Excelera’s ability to prevent and guard against cybersecurity attacks;

 

  ● Excelera’s reliance on third party service providers for processing payments, web and mobile operating systems, software, background checks, and insurance policies;

 

  ● seasonal sales fluctuations;

 

  ● Excelera’s future capital requirements and sources and uses of cash;

 

  ● the outcome of any known and unknown litigation and regulatory proceedings, including the occurrence of any event, change or other circumstances, including the outcome of any legal proceedings that may be instituted against Future Health, Excelera and Seller following the announcement of the Business Combination Agreement and the transactions contemplated therein, that could give rise to the termination of the Business Combination Agreement;

 

  ● Excelera’s ability to maintain and protect its brand and its intellectual property; and

 

  ● other factors detailed under the section entitled “Risk Factors” in the Registration Statement filed in connection with the Business Combination.

 

The forward-looking statements contained herein are based on current expectations and beliefs concerning future developments and their potential effects on Future Health and/or Excelera. There can be no assurance that future developments affecting Future Health and/or Excelera will be those that Future Health and/or Excelera have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control or the control of Excelera), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in the Registration Statement filed in connection with the Business Combination. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by the potential business or economic disruptions caused by current and future pandemics, such as the COVID-19 pandemic and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. Future Health, Excelera and Seller undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  FUTURE HEALTH ESG CORP.
   
Date: October 12, 2022 By: /s/ Bradley A. Bostic
    Name: Bradley A. Bostic
    Title: Chief Executive Officer

 

 

 EX-101.SCH 2 fhlt-20221007.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 fhlt-20221007_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 4 fhlt-20221007_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Units, each consisting of one share of common stock and one-half of one redeemable warrant [Member] Common Stock [Member] Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share Units, each consisting of one share of common stock and one-half of one redeemable warrant EX-101.PRE 5 fhlt-20221007_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Oct. 07, 2022
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 07, 2022
Entity File Number 001-40788
Entity Registrant Name Future Health ESG Corp.
Entity Central Index Key 0001851182
Entity Tax Identification Number 86-2305680
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 8 The Green
Entity Address, Address Line Two Suite 12081
Entity Address, City or Town Dover
Entity Address, State or Province DE
Entity Address, Postal Zip Code 46260
City Area Code 833
Local Phone Number 388-8734
Written Communications true
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units, each consisting of one share of common stock and one-half of one redeemable warrant [Member]  
Title of 12(b) Security Units, each consisting of one share of common stock and one-half of one redeemable warrant
Trading Symbol FHLTU
Security Exchange Name NASDAQ
Common Stock [Member]  
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol FHLT
Security Exchange Name NASDAQ
Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share [Member]  
Title of 12(b) Security Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share
Trading Symbol FHLTW
Security Exchange Name NASDAQ
XML 7 tm2228104d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001851182 2022-10-07 2022-10-07 0001851182 fhlt:UnitsEachConsistingOfOneShareOfCommonStockAndOnehalfOfOneRedeemableWarrantMember 2022-10-07 2022-10-07 0001851182 us-gaap:CommonStockMember 2022-10-07 2022-10-07 0001851182 fhlt:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember 2022-10-07 2022-10-07 iso4217:USD shares iso4217:USD shares 0001851182 false 8-K 2022-10-07 Future Health ESG Corp. DE 001-40788 86-2305680 8 The Green Suite 12081 Dover DE 46260 833 388-8734 true false false false Units, each consisting of one share of common stock and one-half of one redeemable warrant FHLTU NASDAQ Common stock, par value $0.0001 per share FHLT NASDAQ Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share FHLTW NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 4 24 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://futurehealthesgcorp.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2228104d1_8k.htm fhlt-20221007.xsd fhlt-20221007_def.xml fhlt-20221007_lab.xml fhlt-20221007_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2228104d1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 4, "dts": { "definitionLink": { "local": [ "fhlt-20221007_def.xml" ] }, "inline": { "local": [ "tm2228104d1_8k.htm" ] }, "labelLink": { "local": [ "fhlt-20221007_lab.xml" ] }, "presentationLink": { "local": [ "fhlt-20221007_pre.xml" ] }, "schema": { "local": [ "fhlt-20221007.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 2, "memberStandard": 1, "nsprefix": "fhlt", "nsuri": "http://futurehealthesgcorp.com/20221007", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2228104d1_8k.htm", "contextRef": "From2022-10-07to2022-10-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://futurehealthesgcorp.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2228104d1_8k.htm", "contextRef": "From2022-10-07to2022-10-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "fhlt_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share", "label": "Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share [Member]" } } }, "localname": "RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember", "nsuri": "http://futurehealthesgcorp.com/20221007", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "fhlt_UnitsEachConsistingOfOneShareOfCommonStockAndOnehalfOfOneRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Units, each consisting of one share of common stock and one-half of one redeemable warrant", "label": "Units, each consisting of one share of common stock and one-half of one redeemable warrant [Member]" } } }, "localname": "UnitsEachConsistingOfOneShareOfCommonStockAndOnehalfOfOneRedeemableWarrantMember", "nsuri": "http://futurehealthesgcorp.com/20221007", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001104659-22-108137-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-108137-xbrl.zip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